Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines

Core Insights - Vaxcyte is advancing its VAX-31 vaccine candidate through a comprehensive Phase 3 clinical program, with the aim of submitting a Biologics License Application (BLA) [3][4][12] - The OPUS-3 trial is designed to evaluate the safety, tolerability, and immunogenicity of VAX-31 in adults who have previously received pneumococcal vaccination, with topline data expected in the first half of 2027 [1][5] - VAX-31 is designed to cover approximately 95% of invasive pneumococcal disease (IPD) and 88% of pneumococcal pneumonia in U.S. adults aged 50 and older, offering significant incremental coverage over current standard-of-care vaccines [2][12] Company Overview - Vaxcyte, Inc. is a clinical-stage vaccine innovation company focused on developing high-fidelity vaccines to combat bacterial diseases [14] - The company is engineering vaccines using its proprietary XpressCF platform, which allows for the production of complex proteins and antigens [15] - VAX-31 is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate currently in clinical trials, with potential applications in both adult and pediatric populations [12][14] Clinical Trials - The OPUS-1 trial is a pivotal noninferiority trial evaluating VAX-31 for the prevention of IPD and pneumonia in adults, while OPUS-2 evaluates its concomitant administration with a seasonal influenza vaccine [3][5] - Approximately 6,000 adults are expected to be enrolled across the three Phase 3 studies, with about 3,400 receiving VAX-31 [3] - The OPUS-3 trial will involve around 720 participants aged 50 and older, randomized to receive either VAX-31 or an active comparator [5][6] Immunogenicity and Safety - The primary immunogenicity objective of the OPUS-3 trial is to assess serotype-specific immune responses elicited by VAX-31 [9] - Safety and tolerability will be monitored for six months following vaccination, ensuring a comprehensive evaluation of the vaccine's profile [7] Market Potential - The potential for VAX-31 to provide an incremental 14-34% broader coverage for IPD and 19-31% for pneumonia compared to existing vaccines highlights its market significance [2][4][12] - Pneumococcal disease remains a significant health threat, with approximately 225,000 adult hospitalizations annually in the U.S., underscoring the need for improved vaccine options [11]